CEL-SCI CORPORATION Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-14: Disclosure Rule10b51Arr Adopted; Period 2025-10-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Rule10b51Arr Terminated; Period 2025-10-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Non Rule10b51Arr Adopted; Period 2025-10-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Non Rule10b51Arr Terminated; Period 2025-10-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-14 10-Q | Rule10b51Arr Adopted | 2025-10-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Rule10b51Arr Terminated | 2025-10-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Non Rule10b51Arr Adopted | 2025-10-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Non Rule10b51Arr Terminated | 2025-10-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Material Terms Of Trading Arrangement | 2025-10-01..2026-06-30 | None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period ending June 30, 2026. | |
| 2026-07-02 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | Pay Versus Performance (PVP) Year Summary Compensation Table Total for CEO (1) Compensation Actually Paid (CAP) to CEO (2) Average Summary Compensation Table Total for Non-CEO NEOs (3) Average Compensation Actually Paid to Non-CEO NEOs (2) Total Shareholder Return (TSR) (4) Net (Loss) (5) 2025 $ 919… | |
| 2026-07-02 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | Year Summary Compensation Table Total for CEO (1) Compensation Actually Paid (CAP) to CEO (2) Average Summary Compensation Table Total for Non-CEO NEOs (3) Average Compensation Actually Paid to Non-CEO NEOs (2) Total Shareholder Return (TSR) (4) Net (Loss) (5) 2025 $ 919,854 $ 617,863 $ 397,109 $ (7… | |
| 2026-07-02 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | Total Shareholder Return assumes the investment of $100 in our common stock on September 30, 2022 and is based on the closing price of our common stock on September 30, 2025, 2024, and 2023. | |
| 2026-05-15 10-Q | Rule10b51Arr Adopted | 2025-10-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Rule10b51Arr Terminated | 2025-10-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Non Rule10b51Arr Adopted | 2025-10-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Non Rule10b51Arr Terminated | 2025-10-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Material Terms Of Trading Arrangement | 2025-10-01..2026-03-31 | None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period ending March 31, 2026. | |
| 2026-02-17 10-Q | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-17 10-Q | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-17 10-Q | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-17 10-Q | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-17 10-Q | Material Terms Of Trading Arrangement | 2025-10-01..2025-12-31 | None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period ending December 31, 2025. | |
| 2025-12-29 10-K | Rule10b51Arr Adopted | 2024-10-01..2025-09-30 | No | |
| 2025-12-29 10-K | Rule10b51Arr Terminated | 2024-10-01..2025-09-30 | No | |
| 2025-12-29 10-K | Non Rule10b51Arr Adopted | 2024-10-01..2025-09-30 | No | |
| 2025-12-29 10-K | Non Rule10b51Arr Terminated | 2024-10-01..2025-09-30 | No | |
| 2025-08-14 10-Q | Rule10b51Arr Adopted | 2024-10-01..2025-06-30 | No | |
| 2025-08-14 10-Q | Rule10b51Arr Terminated | 2024-10-01..2025-06-30 | No | |
| 2025-08-14 10-Q | Non Rule10b51Arr Adopted | 2024-10-01..2025-06-30 | No | |
| 2025-08-14 10-Q | Non Rule10b51Arr Terminated | 2024-10-01..2025-06-30 | No | |
| 2025-05-14 10-Q | Rule10b51Arr Adopted | 2024-10-01..2025-03-31 | No | |
| 2025-05-14 10-Q | Rule10b51Arr Terminated | 2024-10-01..2025-03-31 | No | |
| 2025-05-14 10-Q | Non Rule10b51Arr Adopted | 2024-10-01..2025-03-31 | No | |
| 2025-05-14 10-Q | Non Rule10b51Arr Terminated | 2024-10-01..2025-03-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |